Fast Facts for Board Review

Biologics for Psoriasis

Author and Disclosure Information

 

Practice Question Answers

1. Which biologic is administered as an intravenous infusion?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

2. Which biologic is dosed based on body weight?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

3. Which biologic has been shown to worsen existing Crohn disease?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

4. Which biologic is a fusion protein?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

5. Which biologic has been shown to cause reversible posterior leukoencephalopathy syndrome?

a. adalimumab

b. etanercept

c. infliximab

d. secukinumab

e. ustekinumab

Pages

Next Article:

Biologics for Pediatric Psoriasis Patients?

Related Articles

  • Fast Facts for Board Review

    Allergic Contact Dermatitis, Part 4

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Fast Facts for Board Review

    Viruses, Part 2: RNA Viruses

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...

  • Fast Facts for Board Review

    Genetic Pathways, Part 2

    As part of our commitment to resident education, Cutis is excited to offer this monthly section with board-relevant, easy-to-review...